Researchers testing CAR T-Cell therapy to treat multiple sclerosis
UC expert featured in Precision Medicine Online article
The University of Cincinnati's Aram Zabeti was featured in a Precision Medicine Online article discussing a new trial testing CAR T-cell therapy to treat multiple sclerosis.
UC is a trial site for the Phase 1 Breakfree-2 trial, sponsored by Bristol Myers Squibb. MS occurs when the immune system mistakenly attacks the myelin that protects and covers nerve fibers, disrupting the communication between the brain and the rest of the body and leading to a wide range of symptoms.
In CAR T-cell therapy, patient's immune cells are collected and genetically modified to recognize and eliminate the malfunctioning immune cells that drive MS. Once modified, they are infused back into the patient.
"We want to make sure they're safe," and that the new cells do not cause additional harm or damage, said Zabeti, associate professor of neurology at UC’s College of Medicine and director of the Waddell Center for MS. "We're hoping [patients] might not need any re-treatment," he added, but that's an area in need of further study.
Read the Precision Medicine Online article.
Read more about the trial at UC.
For more information on trial eligibility and enrollment for this and other MS trials open at UC, please contact trial coordinator Sara Esmaeli at esmaeisr@ucmail.uc.edu.
Featured photo at top illustrating CAR-T cells attacking a malfunctioning immune cell. Photo/selvanegra/iStock Photo.
Related Stories
What Is Public Health Nursing? Career path and whether it’s right for you
April 6, 2026
When nurses consider graduate school, many immediately think of becoming a nurse practitioner. But there is another advanced path that is growing in demand, one focused not on treating individual patients, but on improving the health of entire communities: public health nursing.
A day of hoops and fun supports families impacted by homelessness
April 6, 2026
CPS All-Star Showcase returned to UC’s Fifth Third Arena, Saturday, April 4, highligting the partnership between Cincinnati Public Schools and the University of Cincinnati. Local media covered the daylong sports event which showcased some Cincinnati's finest high school athletes. Proceeds from the event benefited Project Connect.
What is the 'cicada' COVID variant?
April 6, 2026
A formerly rare strain of COVID, BA.3.2, now is showing up in Ohio and 24 other states. Experts say so far it hasn't caused illness any more severe than other strains, but it might be somewhat more resistant to vaccines, as 91.7 WVXU News recently reported. Scientists have nicknamed the variant "cicada" due to its former low profile and current resurgence.